Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing research and development and the growing prevalence of neuroendocrine cancer are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. The side effects associated with neuroendocrine cancer treatment are expected to hamper the market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Unmet Needs
5.2. Supply Chain
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. Sunitinib Malate*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Everolimus
7.4. Lanreotide
7.5. Octreotide
7.6. Others
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment Segment
8.2. Surgery*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chemotherapy
8.4. Targeted Therapy
8.5. Radiotherapy
8.6. Others
9. By End user
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
9.2.1.1. Introduction
9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Oncology Centers
9.4. Ambulatory Surgical Center
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Pfizer Inc.
12.3. Ipsen
12.4. Tarveda Therapeutics
12.5. Progenics Pharmaceuticals, Inc.
12.6. Hutchison Medipharma Limited
12.7. Dauntless Pharmaceuticals Inc.
12.8. Exelixis, Inc.
12.9. Advanced Accelerator Applications
12.10. Argos Therapeutics Inc
LIST NOT EXHAUSTIVE
13. Global Neuroendocrine Cancer Market – DataM
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us